The recent regulatory shift in Indonesia's healthcare sector, marked by the enactment of Government Regulation No. 28 of 2024, introduces new opportunities while establishing higher standards for the distribution of pharmaceuticals, medical devices, and household health supplies. This article explores these developments, emphasizing the heightened compliance requirements and investment prospects within this rapidly expanding market. From quality assurance to pharmacovigilance obligations, the regulations are designed to protect public health and provide a solid foundation for growth in Indonesia’s healthcare industry.

Dentons HPRP's lawyers, including Nashatra Prita (Partner), who brings extensive experience in healthcare and regulatory law, along with Yasyfa Alifya Radiany (Associate), analyze the potential impacts of these regulatory changes on local and international stakeholders. Their insights not only clarify the complexities of GR 28/2024 but also highlight strategic approaches essential for businesses to navigate and succeed within the evolving compliance landscape.

Check the full article here [link]

For more information on our services, please contact the Partner listed under Key Contact.